Last reviewed · How we verify
Cisplatin (or Carboplatin)
Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and transcription to kill rapidly dividing cancer cells.
Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and transcription to kill rapidly dividing cancer cells. Used for Metastatic testicular cancer, Ovarian cancer, Non-small cell lung cancer.
At a glance
| Generic name | Cisplatin (or Carboplatin) |
|---|---|
| Also known as | Platinol (Cisplatin), Paraplatin (Carboplatin), DDP,CBP |
| Sponsor | Biocad |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
These platinum compounds enter cancer cells and covalently bind to DNA, creating intrastrand and interstrand cross-links that distort the DNA helix. This prevents DNA synthesis and repair, triggering apoptosis in cancer cells. Both agents are non-cell-cycle-phase-specific but are most effective against rapidly dividing cells.
Approved indications
- Metastatic testicular cancer
- Ovarian cancer
- Non-small cell lung cancer
- Head and neck cancer
- Bladder cancer
- Gastric cancer
Common side effects
- Nephrotoxicity (kidney damage)
- Ototoxicity (hearing loss)
- Nausea and vomiting
- Myelosuppression (bone marrow suppression)
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
- Electrolyte abnormalities (hypomagnesemia, hypokalemia)
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin (or Carboplatin) CI brief — competitive landscape report
- Cisplatin (or Carboplatin) updates RSS · CI watch RSS
- Biocad portfolio CI